Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 6
Submit an article Journal homepage
651
Views
38
CrossRef citations to date
0
Altmetric
Review

Role of interferons in the treatment of severe acute respiratory syndrome

Jindrich Cinatl Jr Klinikum der Johann Wolfgang Goethe-Universitat, Institut fur Medizinische Virologie, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. [email protected]
,
Martin Michaelis Klinikum der Johann Wolfgang Goethe-Universitat, Institut fur Medizinische Virologie, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. [email protected]
,
Martin Scholz Klinikum der Johann Wolfgang Goethe-Universitat, Institut fur Medizinische Virologie, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. [email protected]
&
Hans Wilhelm Doerr Klinikum der Johann Wolfgang Goethe-Universitat, Institut fur Medizinische Virologie, Paul Ehrlich-Str. 40, 60596 Frankfurt am Main, Germany. [email protected]
Pages 827-836 | Published online: 23 Feb 2005

Bibliography

  • STADLER K, MASIGNANI V, EICKMANN M et al.: SARS-beginning to understand a new virus. Nat. Rev Microbiol. (2003) 1:209–218.
  • PEIRIS JS, YUEN KY, OSTERHAUS AD, STOHR K: The severe acute respiratory syndrome. N Engl. J. Med. (2003) 349:2431–2441.
  • VASTAG B: Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS. JAMA (2003) 290:1695–1696.
  • DAVIDSON A, SIDDELL S: Potential for antiviral treatment of severe acute respiratory syndrome. Carr: Opin. Infect. Dis. (2003) 16:565–571.
  • LEE N, HUI D, WU A et al.: A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl. J. Med. (2003) 348:1986–1994.
  • LOUTFY MR, BLATT LM, SIMINOWITCH KA et al.: Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome. JAMA (2003) 290:3222–3228.
  • •Preliminary, uncontrolled study of patients with SARS using treatment with IFN alfacon-1 improved disease outcome.
  • POUTANEN SM, LOW DE, HENRY B et al.: Identification of severe acute respiratory syndrome in Canada. N Engl. J. Med. (2003) 348:1995–2005.
  • SO LK, LAU AC, YAM LY et a/.: Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet (2003) 361:1615–1617.
  • TSANG KW, HO PL, 001 GC et al.: A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl. J. Med. (2003) 348:1977–1985.
  • ZHAO Z, ZHANG F, XU M et al.: Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J. Med. Microbiol. (2003) 52:715–720.
  • •First clinical trial describing use of IFN-a for SARS.
  • BOOTH CM, MATUKAS LM, TOMLINSON GA et al.: Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JA/VIA (2003) 289:2801–2809.
  • CINATL J JR, MORGERNSTERN B, BAUER G, CHANDRA P, RABENAU H, DOERR HW: Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet (2003) 361:2045–2046.
  • CHU CM, CHENG VCC, HUNG IFN et al.: Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Vaccine (2004) 59:252–256.
  • SUI J, WENHUI L, MURAKAMI A et al.: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to 51 protein that blocks receptor association. Proc. Nati Acad. Sci. USA (2004) 101:2536–2541.
  • ZHANG Y, LI T, FU L et al.: Silencing SARS-CoV spike protein expression in cultured cells by RNA interference. FEBS Lett. (2004) 560:141–146.
  • CINATL J JR, MORGERNSTERN B, BAUER G, CHANDRA P, RABENAU H, DOERR HW: Treatment of SARS with human interferons. Lancet (2003) 362:293–294.
  • •First in vitro study that reports on the effects of IFNs on SCV replication; comparison of different I...PNs in two different cell culture systems.
  • HAAGMANS BL, KUIKEN T, MARTINA BE et al.: Pegylated interferon-a protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 2004 10:290–293.
  • •Demonstration that pegylated INF-a protects type 1 pneumocytes from SCV infection in cynomolgus macaques.
  • HENSLEY LE, FRITZ EA, JAHRLING PB et al.: Interferon-13 la and SARS coronavirus replication. Emerg. Infect. Dis. (2004) 10:317–319.
  • •Investigation of the influence of IFN-I3-la on SCV replication in Vero cells.
  • SEN GC: Viruses and interferons. Annu. Rev. Microbiol. (2001) 55:255–281.
  • KATZE MG, HE Y, GALE M JR: Viruses and interferon: a fight for supremacy. Nat. Rev Immunol. (2002) 2:675–687.
  • UROSEVIC N: Is flavivirus interferon type I-independent? Immunol. Cell Biol. (2003) 81:224–229.
  • SHUAI K, LIU B: Regulation olJAK-STAT signalling in the immune system. Nat. Rev Immunol. (2003) 3:900–911.
  • KISSELEVA T, BHATTACHARYA S, BRAUNSTEIN J, SCHINDLER CW: Signalling through the JAK/STAT pathway, recent advances and future challenges. Gene (2002) 285:1–24.
  • LEVY DE: Whence interferon? Variety inthe production of interferon in response to viral infection. J. Exp. Med. (2002) 195:F15–F18.
  • DE VEER MJ, HOLKO M, FREVEL M et al.: Functional classification of interferon-stimulated genes identified using microarrays. Leukoc. Biol. (2001) 69:912–920.
  • DER SD, ZHOU A, WILLIAMS BR, SILVERMAN RH: Identification of genes differentially regulated by interferon a,3, or using oligonucleotide arrays. Proc. Nati Acad. ScL USA (1998) 95:15623–15628.
  • SAMUEL C: Antiviral action of interferons. Clin. Microbiol. Rev (2001) 14:778–809.
  • ZHOU A, PARANJAPE JM, WILLIAMS BR, SILVERMAN RH: Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology (1999) 258:435–440.
  • ESKILDSEN E, JUSTESEN J, SCHIERUP MH, HARTMANN R: Characterization of the 2'-5'-oligoadenylate synthetase ubiquitin-like family. Nucleic Acids Res. (2003) 31:3166–3173.
  • GOODBOURN S, DIDCOCK L, RANDALL RE: Interlerons: cell signalling. Immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. (2000) 81:2341–2364.
  • CHAWLA-SARKAR M, LINDNER DJ, LIU YF et a/.:Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 8:237–249.
  • PATEL RC, SEN GC: PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. (1998) 17:4379–4390.
  • ABRAHAM N, STOJDL DF, DUN CAN PI et al.: Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. [Biol. Chem. (1999) 274:5953–5962.
  • BALACHANDRAN S, ROBERTS PC, BROWN LE et al.: Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity (2000) 13:129–141.
  • HALLER 0, ACKLIN M, STAEHELI P:Influenza virus resistance of wild mice: wild-type and mutant Mx allels occur at comparable frequencies. J. Interferon Res. (1987) 7:647–656.
  • STAEHLI P: Interferon-induced proteins and the antiviral state. Adv. Virus Res. (1990) 38:147–200.
  • HALLER 0, KOCHS G: Interferon-induced Mx proteins: dynamin-like GTPases with antiviral activity. Traffic (2002) 3:710–717.
  • JANZEN C, KOCHS G, HALLER 0: A monomeric GTPase-negative MxA mutant with antiviral activity. J. Vim/. (2000) 74:15427–15432.
  • ANDERSON SL, CARTON JM, LOU J, XING L, RUBIN BY: Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology (1999) 256:8–14.
  • PATTERSON JB, THOMIS DC, HANS SL, SAMUEL CE: Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology (1995) 210:508–511.
  • SAUNDERS LR, BARBER GN: The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB (2003) 17:961–983.
  • LIU Y, EMERSON RB, SAMUEL CE: Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice variants of the interferon inducible double-stranded RNA-specific adenosinase ADAM,. j Biol. Chem. (1999) 274:18351–18358.
  • JAYAN GC, CASEY JL: Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2. I Virol (2002) 76:3819–3827.
  • SPERBER SJ, HAYDEN FG: Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. J. Interferon Res. (1989) 9:285–293.
  • PEI J, SEKELLICK MJ, MARCUS PI, CHOI IS, COLLISON EW: Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory ilness. J. Interferon Cytokine Res. (2001) 21:1071–1077.
  • MINAGAWA H, TAKENAKA A, MOHRI S, MORI R: Protective effect of recombinant interferon beta against mouse hepatitis virus infection. Antiviral Res. (1987) 8:85–95.
  • LUCCHIARI MA, MARTIN JP, MOD OLELL M, PEREIRA CA: Acquired immunity of A/J mice to mouse hepatitis virus 3 infection: dependence on interferon-gamma synthesis and macrophage sensitivity to interferon-gamma." Gen. Viral. (1991) 72:1317–1322.
  • WEINGARTL HM, DERBSHIRE JB: Antiviral activity against transmissible gastroenteritis virus, and cytotoxicity, of natural porcine interferons alpha and beta. Can. J. Vet. Res (1991) 55:143–149.
  • COLLINS AR: Interferon gamma potentiates human coronavirus 0C43 infection of neuronal cells by modulation of HLA class I expression. Immunol Invest. (1995) 24:977–986.
  • HERTZIG T, SCANDELLA E, SCHELLE B et al: Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J. Gen. Virol (2004) (In Press).
  • FUCHIZAKI U, KANEKO S, NAKAMOTO Y et al.: Synergistic antiviral effect of a combination of mouse interferon-a and interferon-y on mouse hepatitis virus. J. Med. Viral. (2003) 69:188–194.
  • BAUDOUX P, CARRAT C, BESNARDEAU L, CHARLEY B, LAUDE H: Coronavirus psedoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. Viral. (1998) 72:8636–8643.
  • COLLINS AR: Comparison of the replication of distinct strains of human coronavirus 0C43 in organotypic human colon cells (Caco-2) and mouse intestine. Adv. Exp. Med. Biol. (1990) 276:497–503.
  • PITKARANTA A, NOKSO-KOIVISTO J, JANTTI V, TAKALA A, KILPIT, HOVI T: Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J. Gin Virol (1999) 14:199–205.
  • TURNER RB, FELTON A, KOSAK K, KELSEY DK, MESCIEVITZ CK: Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J. Infect. Dis. (1986) 154:443–447.
  • TYRRELL DA: The efficacy and toleranceof intranasal interferons: studies at the Common Cold Unit. I Antimicrob. Chemother. (1986) 18:153–156.
  • MELIAN EB, PLOSKER GL: Interferon alfacon-1. Drugs (2001) 61: 1661-1691.
  • ENSERINK M: Interferon shows promisein monkeys. Science (2004) 303:1273–1275.
  • HARLE P, LAURET E, PITHA PM, DE MAEYER E, CARR DJ: Expression of human and macaque type I IFN transgenes interferes with HSV- replication at the transcriptional and translational levels: IFN-B is more potent than IFN-a2. Virology (2001) 290:237–248.
  • ANTONETTI F, FINOCCHIARO 0, MASCIA M, TERLIZZESE MG, JABER A: A comparison of the biological activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. (2002) 22:1181–1184.
  • ANTONELLI G, SCAGNOLARI C, VINCENZI E, CLEMENTI H: Treatment of SARS with human interferons. Lancet (2003) 362:1158; author reply 1158–1159.
  • STROHER U, DICARO A, STRONG JEet al.: Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J. Infect. Dis. (2004) 189:1164–1167.
  • TAN ELC, 001 EE, LIN C-Y et al.: Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. (2004) 10:581–586.
  • MANNS MP, CORNBERG M, WEDEMEYER H: Current and future treatment of hepatitis C. Indian J. Gastroenterol (2001) 20:C47–051.
  • BAKER DE: Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev. Gastroenterol Disord. (2003) 3:93–109.
  • PEPINSKY RB, LEPAGE DJ, CHAKRABORTY A et al: Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. Pharmacol Exp. Ther. (2001) 297:1059–1066.
  • LANG ZW, ZHANG LJ, ZHANG SJ et al.: A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology (2003) 35:526–531.
  • DE GROOT AS: How the SARS vaccine effort can learn from HIV-speeding towards the future, learning from the past. Vaccine (2003) 21:4095–4104.
  • HO JC, 00I GC, MOK TY et al: High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am. J. Respic Grit. Care Med. (2003) 168:1449–1456.
  • GLASS WG, ROSENBERG HF, MURPHY PM: Chemokine regulation of inflammation during acute viral infection. Carr. Opin. Allergy Clin. Ingnunel (2003) 3:467–473.
  • GNIADEK P, AKTAS 0, WANDINGER KP et al.: Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. Neureingnunel (2003) 137:187-196. Websites

Websites

  • http://www.cdc.gov/ncidod/sars/ clinicalguidance.htm CDC guidance and recommendations for SARS.
  • http://www.who.int/csr/sars/en WHO SARS website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.